A “gamechanger” new pill could double survival time in patients with the deadliest form of cancer, according to the results of a clinical trial.
Pancreatic cancer is difficult to treat as it is often found late and more than half of patients are only diagnosed after it has spread.
However, a new smart drug called Daraxonrasib could dramatically improve how long patients live after a diagnosis.
How new pill could transform cancer treatment
Daraxonrasib increased the survival time of patients with pancreatic cancer to an average of 13.2 months, compared to 6.6 and 6.7 months for patients who had chemotherapy, the trial found.
